Compare ARWR & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | ALKS |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.8B |
| IPO Year | 1993 | 1991 |
| Metric | ARWR | ALKS |
|---|---|---|
| Price | $70.94 | $29.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $60.70 | $42.85 |
| AVG Volume (30 Days) | ★ 3.3M | 2.1M |
| Earning Date | 11-25-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | N/A | ★ 2.02 |
| Revenue | $829,448,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.22 |
| P/E Ratio | ★ N/A | $14.46 |
| Revenue Growth | ★ 23258.15 | 1.08 |
| 52 Week Low | $9.57 | $25.17 |
| 52 Week High | $72.36 | $36.45 |
| Indicator | ARWR | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 78.58 | 46.86 |
| Support Level | $60.29 | $27.81 |
| Resistance Level | $71.50 | $29.80 |
| Average True Range (ATR) | 5.14 | 0.89 |
| MACD | 1.73 | 0.00 |
| Stochastic Oscillator | 95.82 | 54.02 |
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.